# Reading list

> The Peptide Woman’s reading list — The Peptide Woman reading list: primary-care records, HSDD diagnosis, bremelanotide trials, critical analyses and prescribing information.

The record study supplies the opening problem. The drug papers address a narrower clinical question.

## Care records and diagnosis

[The primary-care observational study](https://doi.org/10.1007/s11606-024-09004-1) reports the management gap across female sexual dysfunction and erectile dysfunction. It supplies no trial evidence for closing that gap with bremelanotide.

[The diagnostic review](https://doi.org/10.7759/cureus.49690), [the baseline-activity analysis](https://doi.org/10.1080/0092623X.2026.2651862) and [the expert round-table discussion](https://doi.org/10.1159/000535587) address different disputes around low desire. The baseline paper's title contains language I question in the [diagnosis essay](/diagnosis).

## Bremelanotide results

[The randomized RECONNECT report](https://pubmed.ncbi.nlm.nih.gov/31599840/) and its [open-label extension](https://pubmed.ncbi.nlm.nih.gov/31599847/) offer different kinds of follow-up. The [regulatory critique](https://doi.org/10.1136/dtb.2021.000020) challenges the clinical benefit; the [pharmacotherapy review](https://doi.org/10.1177/10600280241253273) discusses limited efficacy and adverse effects.

[The medical-treatment review](https://doi.org/10.1016/j.ucl.2022.02.001) specifies the premenopausal generalized acquired HSDD indication. The [prescribing information](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9) is the source for the cardiovascular contraindications described here.

## References

[1] Gap in Sexual Dysfunction Management Between Male and Female Patients Seen in Primary Care: An Observational Study. https://doi.org/10.1007/s11606-024-09004-1
[2] Understanding Hypoactive Sexual Desire Disorder (HSDD) in Women: Etiology, Diagnosis, and Treatment. https://doi.org/10.7759/cureus.49690
[3] Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials https://pubmed.ncbi.nlm.nih.gov/31599840/
[4] Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. https://doi.org/10.1136/dtb.2021.000020
[5] Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women. https://doi.org/10.1177/10600280241253273
[6] Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder https://pubmed.ncbi.nlm.nih.gov/31599847/
[7] Bremelanotide Injection — US Prescribing Information (DailyMed/FDA) https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9
[8] Quantification of "Mercy Sex" in Heterosexual Women. https://doi.org/10.1080/0092623X.2026.2651862
[9] What Women Want? The State of the Art regarding the Treatment of Young Women with Hypoactive Sexual Desire Disorder. https://doi.org/10.1159/000535587
[10] Medical Treatment of Female Sexual Dysfunction. https://doi.org/10.1016/j.ucl.2022.02.001

---

I argue here about published research on women's sexual health; these pages provide neither medical advice nor clinical services nor commercial offerings.